Where We’ve Been
Early on, we recognized the power and potential of active cellular immunotherapy (ACI) to fight cancer. And in April 2009, we announced that the pivotal PROVENGE Phase 3 IMPACT study in men with advanced prostate cancer had met its primary endpoint of improving overall survival compared to the control arm.
On April 29, 2010, PROVENGE® (sipuleucel-T) received FDA approval for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. It is the first in a new class of cancer treatments called autologous cellular immunotherapies.
If you believe that passion and dedication can ultimately increase hope for those with cancer, we should meet.